Company Analysis China Pharma Holdings Inc
1. Summary
Advantages
- The stock's return over the last year (783.25%) is higher than the sector average (37.03%).
- Current debt level 2.4E-5% is below 100% and has decreased over 5 years from 20.25%.
Disadvantages
- Price (1.63 $) is higher than fair price (1.11 $)
- Dividends (0%) are below the sector average (0%).
- The company's current efficiency (ROE=-0.000122%) is lower than the sector average (ROE=0%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| China Pharma Holdings Inc | Index | ||
|---|---|---|---|
| 7 days | 16.8% | -3.7% | -0.6% |
| 90 days | 1207.4% | 0% | 5.7% |
| 1 year | 783.3% | 37% | 9% |
CPHI vs Sector: China Pharma Holdings Inc has outperformed the "" sector by 746.22% over the past year.
CPHI vs Market: China Pharma Holdings Inc has outperformed the market by 774.28% over the past year.
Highly volatile price: CPHI is significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical deviations of more than +/- 15% per week.
Long period: CPHI with weekly volatility of 15.06% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1.63 $) is higher than the fair price (1.11 $).
Price is higher than fair: The current price (1.63 $) is 31.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (0).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (61.83).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is higher than that of the sector as a whole (0).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (20.82).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is higher than that of the sector as a whole (0).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (16).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is higher than that of the sector as a whole (0).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (27.04).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 9.97% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (9.97%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (-0.000122%) is lower than that of the sector as a whole (0%).
ROE vs Market: The company's ROE (-0.000122%) is lower than that of the market as a whole (43%).
5.5. ROA
ROA vs Sector: The company's ROA (-6.4E-5%) is lower than that of the sector as a whole (0%).
ROA vs Market: The company's ROA (-6.4E-5%) is lower than that of the market as a whole (23.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
